Cellosaurus logo
expasy logo

Cellosaurus CHLA-9 (CVCL_M150)

[Text version]
Cell line name CHLA-9
Synonyms CHLA9
Accession CVCL_M150
Resource Identification Initiative To cite this cell line use: CHLA-9 (RRID:CVCL_M150)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: MD Anderson Cell Lines Project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Doubling time: 20 hours (PubMed=20922763); 51 hours (PubMed=24312454).
Omics: Deep exome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: scRNAseq analysis.
Omics: Transcriptome analysis by RNAseq.
Sequence variations
  • Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=25010205).
  • Mutation; HGNC; 11355; STAG2; Simple; p.Val628insThrAspIle; Zygosity=Unspecified (PubMed=25010205).
Disease Primitive neuroectodermal tumor (NCIt: C3716)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_6583 ! CHLA-10
Sex of cell Female
Age at sampling 14Y
Category Cancer cell line
STR profile Source(s): COG; PubMed=20922763; PubMed=24312454; PubMed=25010205


Run an STR similarity search on this cell line
Web pages http://www.cccells.org/dl/EFT_Lines_DataSheets/CHLA-9_Cell_Line_Data_Sheet_COGcell_org.pdf

PubMed=15289350; DOI=10.1158/0008-5472.CAN-04-0377
Batra S., Reynolds C.P., Maurer B.J.
Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.
Cancer Res. 64:5415-5424(2004)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=24312454; DOI=10.1371/journal.pone.0080060
May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L., Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.
Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.
PLoS ONE 8:E80060-E80060(2013)

PubMed=25010205; DOI=10.1371/journal.pgen.1004475
Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S., Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y., Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H., Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S., Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.
The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation.
PLoS Genet. 10:E1004475-E1004475(2014)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cell line databases/resources Cell_Model_Passport; SIDM01534
DepMap; ACH-001034
Encyclopedic resources Wikidata; Q54812509
Gene expression databases GEO; GSM1676339
GEO; GSM1701626
GEO; GSM4368462
Polymorphism and mutation databases Cosmic; 2228220
Entry history
Entry creation06-May-2013
Last entry update21-Mar-2023
Version number19